SLDB NASDAQ
Credit Risk of going bust: higher than 51% of companies Debt: 3.1% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.03 (down 99.5%), Solid Biosciences Inc. would be worth roughly what it owes.
Total debt $20.2M against a stock market value of $623.0M.
Distance to default 5.05 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $10.1M (short-term plus half of long-term), stock volatility 78.1%; Altman Z'' 2.57. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Charlestown, MA 02129
US
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Brooks Gabriel | S-Sale | 4,374 | $5.62 | 2026-10-19 |
| Brooks Gabriel | M-Exempt | 9,750 | — | 2026-10-18 |
| Brooks Gabriel | M-Exempt | 9,750 | — | 2026-10-18 |
| SMITH IAN F | M-Exempt | 3,440 | — | 2026-10-02 |
| SMITH IAN F | M-Exempt | 3,440 | — | 2026-10-02 |